Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) Loses -71.92% From High. Why That Could Change?
Currently, there are 361.49M common shares owned by the public and among those 179.54M shares have been available to trade. The company’s stock has a 5-day price change of 19.65% and -28.11% over the past three months. LXRX shares are trading -6.84% year to date (YTD), with the 12-month market performance down to -57.27% lower. […]
Why Should You Put Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) On Your Portfolio?
Currently, there are 361.49M common shares owned by the public and among those 179.54M shares have been available to trade. The company’s stock has a 5-day price change of 20.28% and -19.13% over the past three months. LXRX shares are trading -13.68% year to date (YTD), with the 12-month market performance down to -60.65% lower. […]
These Numbers Could Change Investor Views For Lexicon Pharmaceuticals Inc (NASDAQ: LXRX)
Currently, there are 361.49M common shares owned by the public and among those 179.54M shares have been available to trade. The company’s stock has a 5-day price change of 2.44% and -24.91% over the past three months. LXRX shares are trading -28.23% year to date (YTD), with the 12-month market performance down to -73.76% lower. […]
Why Should You Put Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) On Your Portfolio?
Currently, there are 361.49M common shares owned by the public and among those 179.54M shares have been available to trade. The company’s stock has a 5-day price change of 12.28% and -34.39% over the past three months. LXRX shares are trading -29.94% year to date (YTD), with the 12-month market performance down to -74.64% lower. […]
Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) Has Another Chance To Impress You
Currently, there are 361.49M common shares owned by the public and among those 179.54M shares have been available to trade. The company’s stock has a 5-day price change of 57.08% and -24.72% over the past three months. LXRX shares are trading -22.75% year to date (YTD), with the 12-month market performance down to -73.09% lower. […]
Is Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) Proving The Doubters Wrong?
Lexicon Pharmaceuticals Inc (LXRX) concluded trading on Wednesday at a closing price of $0.33, with 5.22 million shares of worth about $1.72 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -80.18% during that period and on March 26, 2025 the price saw a […]
Are Analysts Expecting A Better 2025 For Lexicon Pharmaceuticals Inc (LXRX)?
Lexicon Pharmaceuticals Inc (LXRX) concluded trading on Wednesday at a closing price of $0.36, with 5.84 million shares of worth about $2.1 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -78.97% during that period and on Wednesday the price saw a loss of […]
Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) – Suitable For Long Term Buy?
Currently, there are 361.49M common shares owned by the public and among those 179.54M shares have been available to trade. The company’s stock has a 5-day price change of 21.22% and -48.23% over the past three months. LXRX shares are trading -51.97% year to date (YTD), with the 12-month market performance down to -84.24% lower. […]
Reviewing The Case For Lexicon Pharmaceuticals Inc (LXRX) Going Higher
Currently, there are 361.49M common shares owned by the public and among those 179.90M shares have been available to trade. Insiders at the company have transacted a total of 0 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, […]
Growing Through Challenges? – Lexicon Pharmaceuticals Inc (LXRX)
Currently, there are 244.93M common shares owned by the public and among those 238.68M shares have been available to trade. Insiders at the company have transacted a total of 56 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 47 of these insider trades were purchases, […]
